Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients(982 views) Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M
Keywords: Breast Carcinoma, Multidrug Resistance, P-Glycoprotein, Technetium-99m-Sestamibi, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Monoclonal Antibody, Monoclonal Antibody Mrk 16, Unclassified Drug, Article, Autoradiography, Breast Cancer, Cancer Resistance, Clinical Article, Controlled Study, Drug Uptake, Female, Human, Intravenous Drug Administration, Priority Journal, Protein Expression, Radioisotope Distribution, Breast Neoplasms, Multiple, Immunoenzyme Techniques, Neoplasm Proteins, Risk Factors, Technetium Tc 99m Sestamibi,
Affiliations: Medicina Nucleare, Fac. di Medicina e Chirurgia, Via Pansini, 5, 80131 Naples, Italy
References: Gottesman, M.M., How cancer cells evade chemotherapy: 16th Richard and Hinda Rosenthal foundation award lecture (1993) Cancer Res, 53, pp. 747-75
Chin, K.V., Pastan, I., Gottesman, M.M., Function and regulation of the human multidrug-resistance gene (1993) Adv Cancer Res, 60, pp. 157-180
Van Der Bliek, A.M., Borst, P., Multidrug resistance (1989) Adv Cancer Res, 52, pp. 165-202
Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., Pastan, I., Expression of a multidrug-resistance gene in human tumors and tissues (1987) Proc Natl Acad Sci USA, 84, pp. 265-269
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues (1987) Proc Natl Acad Sci USA, 84, pp. 7735-7738
Goldstein, L.J., Galski, H., Fojo, A., Expression of a multidrug-resistance gene in human cancers (1989) J Natl Cancer Inst, 81, pp. 116-124
Weinstein, R.S., Hansen, K.K., McBeath, R.B., Dalton, W.S., Expression of the MDR1 gene (P-glycoprotein) in breast cancer (1993) Recent Results Cancer Res, 127, pp. 49-54
Piwnica-Worms, D., Chiu, M.L., Budding, M., Kronauge, J.F., Kramer, R.A., Croop, J.M., Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex (1993) Cancer Res, 53, pp. 977-984
Wackers, F.J.T., Berman, D.S., Maddahi, J., Technetium-99m-hexakis 2-methoxy isobutylisonitrile: Human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging (1989) J Nucl Med, 30, pp. 301-311
Hassan, I.M., Sahweil, A., Constantinides, C., Mahmoud, A., Nair, M., Omar, Y.T., Abdel-Dayem, H.M., Uptake and kinetics of 99mTc-hexakis 2-methoxy isobutylisonitrile in benign and malignant lesions of the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Caner, B., Kitapel, M., Unlu, M., Erbengi, G., Calikoglu, T., Gogus, T., Bekdik, C., Technetiutn-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with 99mTc-MDP (1992) J Nucl Med, 33, pp. 319-324
Abdel-Dayem, H.M., Scott, A.M., Macapinlac, H.A., El-Gazzar, A.H., Larson, S.M., Role of thallium-201 chloride and 99mTc-sestamibi in tumor imaging (1994) Nuclear Medicine Annual 1994, pp. 181-234. , Freeman LM, ed. New York: Raven Press Ltd
Khalkhali, I., Mena, I., Diggles, L., Review of imaging techniques for the diagnosis of breast cancer: A new role of prone scintimammography using technetium-99m-sestamibi (1994) Eur J Nucl Med, 21, pp. 357-362
Khalkhali, I., Cutrone, J., Mena, I., Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up (1995) J Nucl Med, 36, pp. 1784-1789
Palmedo, H., Schonburg, A., Grunwald, F., Mallmann, P., Krebs, D., Biersack, H.J., Technetium-99m-MIBI scintimammography for suspicious breast lesions (1996) J Nucl Med, 37, pp. 626-630
Villanueva-Meyer, J., Leonard Jr., M.H., Briscoe, E., Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer (1996) J Nucl Med, 37, pp. 926-930
Duran Cordobes, M., Starzec, A., Delmon-Moingeon, L., Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression (1996) J Nucl Med, 37, pp. 286-289
Del Vecchio, S., Ciarmiello, A., Potena, M.I., In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Hartmann, W.H., Ozzello, L., Sobun, L.H., Stalsberg, H., (1981) Histological Typing of Breast Tumors, 2nd Ed., , Geneva: WHO
Hamada, H., Tsuruo, T., Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies (1986) Proc Natl Acad Sci USA, 83, pp. 7785-7789
Georges, E., Tsuruo, T., Ling, V., Topology of P-glycoprotein as determined by epitope mapping of MRK16 monoclonal antibody (1993) J Biol Chem, 268, pp. 1792-1798
Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., Bunn, P.A., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess (1984) J Immunol Methods, 72, pp. 77-89
Del Vecchio, S., Reynolds, J.C., Blasberg, R.G., Measurement of local Mr 97,000 and 250,000 protein antigen concentration in sections of human melanoma using in vitro quantitative autoradiography (1988) Cancer Res, 48, pp. 5475-5481
Li, P.Y., Del Vecchio, S., Fonti, R., Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (1996) J Nucl Med, 37, pp. 665-672
Hsu, S.M., Raine, L., Fanger, H., Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures (1981) Histochem Cytochem, 29, pp. 577-580
Ballinger, J.R., Hua, H.A., Berry, B.W., Firby, P., Boxen, I., Technetium-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant (1995) Nucl Med Commun, 16, pp. 253-257
Delmon-Moingeon, L.I., Piwnica-Worms, D., Van Den Abbeele, A.D., Holman, B.L., Davison, A., Jones, A.G., Uptake of the cation hexakis (2-methoxyisobutyl-isonitrile)-technetium-99m by human carcinoma cell lines in vitro (1990) Cancer Res, 50, pp. 2198-2202
Schneider, J., Bak, M., Efferth, T., Kaufmann, M., Mattern, J., Volm, M., P-glycoprotein expression in treated and untreated human breast cancer (1989) Br J Cancer, 60, pp. 815-818
Leonardo, E., Valente, G., Cappia, S., Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57 (1994) Int J Cancer, 57, pp. 841-846
Charpin, C., Vielh, P., Duffaud, F., Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and immunohistochemical prognostic indicators (1994) J Natl Cancer Inst, 86, pp. 1539-1545
Verrelle, P., Meissonnier, F., Fonck, Y., Clinical relevance of immunohistochemical detection of multidrug-resistance P-glycoprotein in breast carcinoma (1991) J Natl Cancer Inst, 83, pp. 111-116
Gottesman, M. M., How cancer cells evade chemotherapy: 16th Richard and Hinda Rosenthal foundation award lecture (1993) Cancer Res, 53, pp. 747-75
Chin, K. V., Pastan, I., Gottesman, M. M., Function and regulation of the human multidrug-resistance gene (1993) Adv Cancer Res, 60, pp. 157-180
Van Der Bliek, A. M., Borst, P., Multidrug resistance (1989) Adv Cancer Res, 52, pp. 165-202
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., Pastan, I., Expression of a multidrug-resistance gene in human tumors and tissues (1987) Proc Natl Acad Sci USA, 84, pp. 265-269
Goldstein, L. J., Galski, H., Fojo, A., Expression of a multidrug-resistance gene in human cancers (1989) J Natl Cancer Inst, 81, pp. 116-124
Weinstein, R. S., Hansen, K. K., McBeath, R. B., Dalton, W. S., Expression of the MDR1 gene (P-glycoprotein) in breast cancer (1993) Recent Results Cancer Res, 127, pp. 49-54
Wackers, F. J. T., Berman, D. S., Maddahi, J., Technetium-99m-hexakis 2-methoxy isobutylisonitrile: Human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging (1989) J Nucl Med, 30, pp. 301-311
Hassan, I. M., Sahweil, A., Constantinides, C., Mahmoud, A., Nair, M., Omar, Y. T., Abdel-Dayem, H. M., Uptake and kinetics of 99mTc-hexakis 2-methoxy isobutylisonitrile in benign and malignant lesions of the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Hartmann, W. H., Ozzello, L., Sobun, L. H., Stalsberg, H., (1981) Histological Typing of Breast Tumors, 2nd Ed., , Geneva: WHO
Li, P. Y., Del Vecchio, S., Fonti, R., Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (1996) J Nucl Med, 37, pp. 665-672
Hsu, S. M., Raine, L., Fanger, H., Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures (1981) Histochem Cytochem, 29, pp. 577-580
Ballinger, J. R., Hua, H. A., Berry, B. W., Firby, P., Boxen, I., Technetium-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant (1995) Nucl Med Commun, 16, pp. 253-257
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients
The multidrug-resistant phenotype is characterized by the reduced intracellular retention of several structurally and functionally unrelated cytotoxic compounds due to the energy-dependent pump activity of P- glycoprotein (Pgp). Because (99m)Tc-sestamibi is a suitable transport substrate of Pgp, we tested whether the time-dependent fractional retention of this tracer could be used as an index of Pgp expression in untreated breast carcinomas. Methods: Twenty-seven patients with histologically confirmed breast carcinoma were intravenously injected with 740 MBq (20 mCi) of (99m)Tc-sestamibi, and static planar images of the breast were obtained at 10, 60 and 240 min. The fractional retention of (99m)Tc-sestamibi was then calculated as the ratios between 60 and 10 min (R60/10) and between 240 and 10 min (R240/10) of decay-corrected counts/pixel registered in the region of interest drawn around the tumor. Surgically excised tumors were then obtained from each patient, and Pgp levels were determined using 125I- labeled MRK16 monoclonal antibody and in vitro quantitative autoradiography. Results: The fractional retention of (99m)Tc-sestamibi at 60 and 240 min was significantly higher in tumors with low Pgp levels (Group I, n = 18) as compared to that measured in tumors with high Pgp expression (Group II, n = 9) (13 < 0,001). In particular, R60/10 values were 0.86 and 0.59 in breast carcinomas of Groups I and II, respectively, whereas the values of R240/10 were 0.55 and 0.25 in low- and high-Pgp-expressing tumors, respectively. Conclusion: The determination of fractional retention of (99m)Tc-sestamibi may be used as a simple functional test for Pgp expression in untreated breast cancer. A preliminary estimate of the sensitivity and the specificity of the test indicates its potential use in clinical practice to identify patients with a high probability of developing multidrug resistance.
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients
No results.
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote